Immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during-treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients

被引：0
|
作者：
Ahmad, S
Bacher, P
Lassen, MR
Hoppensteadt, DA
Leitz, H
Walenga, JM
Fareed, J
机构：
[1] Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA
[2] Cent Hosp Hillerod, DK-3400 Hillerod, Denmark
来源：
FASEB JOURNAL | 2002年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A205 / A205
页数：1
相关论文
共 50 条
  • [1] Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients
    Ahmad, S
    Bacher, HP
    Lassen, MR
    Hoppensteadt, DA
    Leitz, H
    Misselwitz, F
    Walenga, JM
    Fareed, J
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2003, 127 (05) : 584 - 588
  • [2] Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies
    Ahmad, S
    Haas, S
    Hoppensteadt, DA
    Lietz, H
    Reid, U
    Bender, N
    Messmore, HL
    Misselwitz, F
    Bacher, P
    Gaikwad, BS
    Jeske, WP
    Walenga, JM
    Fareed, J
    THROMBOSIS RESEARCH, 2002, 108 (01) : 49 - 55
  • [3] Molecular weight-dependence of heparin on the pathogenic responses of anti-heparin-platelet factor 4 antibodies.
    Ahmad, S
    Walenga, JM
    Jeske, WP
    Hoppensteadt, DA
    Bakhos, M
    Fareed, J
    BLOOD, 2000, 96 (11) : 271A - 271A
  • [4] Anti-heparin-platelet factor 4 antibodies do not require heparin/platelet factor 4 for producing platelet and cellular activation
    Walenga, JM
    Ahmad, S
    Jeske, WP
    Wood, JJ
    Amiral, J
    Lewis, BE
    Messmore, HL
    Bakhos, M
    THROMBOSIS AND HAEMOSTASIS, 1999, : 527 - 527
  • [5] Characterization of anti-heparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: Role of the HIT IgG subtype
    Ahmed, S
    Untch, B
    Messmore, HL
    Hoppensteadt, DA
    Walenga, JM
    Fareed, J
    FASEB JOURNAL, 2002, 16 (04): : A204 - A205
  • [6] Anti-heparin-platelet factor 4 antibodies do not require heparin/platelet factor 4 for producing platelet and cellular activation.
    Walenga, JM
    Ahmad, S
    Jeske, WP
    Wood, J
    Amiral, J
    Lewis, BE
    Messmore, H
    BLOOD, 1998, 92 (10) : 180A - 180A
  • [7] Lack of thrombocytopenic response after low-molecular-weight heparins usage is due to the generation of non-functional anti-heparin-platelet factor 4 antibodies
    Ahmad, S
    Walenga, JM
    Jeske, WP
    Hoppensteadt, DA
    Khan, E
    Cella, G
    Messmore, HL
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 316A - 316A
  • [8] Mechanism of low-molecular-weight heparin reversal by platelet factor 4
    Fiore, Martine M.
    Mackie, Ian M.
    THROMBOSIS RESEARCH, 2009, 124 (01) : 149 - 155
  • [9] A systematic approach to profile the functionality of the anti-heparin-platelet factor 4 antibodies
    Krishnamurthy, V
    Ahmad, S
    Hoppensteadt, DA
    Hering, JW
    Untch, B
    Fareed, J
    FASEB JOURNAL, 2001, 15 (04): : A592 - A592
  • [10] Antibodies to platelet factor 4 - Heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin - Clinical implications for heparin-induced thrombocytopenia
    Pouplard, C
    May, MA
    Iochmann, S
    Amiral, J
    Vissac, AM
    Marchand, M
    Gruel, Y
    CIRCULATION, 1999, 99 (19) : 2530 - 2536
12345